Status: Recruiting
Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
This is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Amitzo® in Iranian patients with grade III and IV glioma tumors. No control group is considered in the study design. The primary objective is to evaluate the incidence of hepatic injury in patients with grade III and IV glioma tumors, treated with Amitzo®.
Participants needed: 100
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: NanoAlvandUpdated: Jun 30, 2026Locations: 1
Eligibility criteria
Patients with newly diagnosed grade III or IV glial tumors, or patients who have... [+1]
Patients without a baseline MRI [+1]